Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: Chronic graft-versus-host disease is the strongest factor improving survival

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 577-584

  Valcárcel, David ^a   Martino, Rodrigo ^a   Caballero, Dolores ^a   Martin, Jesus ^a   Ferra, Christelle ^a   Nieto, Jose B ^a   Sampol, Antonia ^a   Bernal, M Teresa ^a   Piñana, Jose L ^a   Vazquez, Lourdes ^a   Ribera, Jose M ^a   Besalduch, Joan ^a   Moraleda, Jose M ^a   Carrera, Dolores ^a   Brunet, M Salut ^a   Perez Simón, Jose A ^a   Sierra, Jorge ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; COTRIMOXAZOLE; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; GANCICLOVIR; LEUKOCYTE ANTIGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT; VIDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; SURVIVAL RATE; UNIVARIATE ANALYSIS; ALLOTRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIAL; DRUG COMBINATION; GRAFT VERSUS HOST REACTION; IMMUNOSUPPRESSIVE TREATMENT; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; BUSULFAN; CHRONIC DISEASE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 39149133203     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.1641     Document Type: Article

References (40)

1. Giralt S, Estey E, Albitar M, et al: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89:4531-4536, 1997
2. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
3. Valcarcel D, Martino R, Sureda A, et al: Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 74:144-151, 2005
4. Cassileth PA, Harrington DP, Appelbaum FR, et al: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649-1656, 1998
5. Gale RP, Park RE, Dubois RW, et al: Delphipanel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leuk Res 23:709-718, 1999
6. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000
7. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332:217-223, 1995
8. Cahn JY, Labopin M, Mandelli F, et al: Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group. Blood 85:575-579, 1995
9. De Witte T, Van BA, Hermans J, et al: Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS: Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 90:3853-3857, 1997
10. Martino R, Caballero MD, Simon JA, et al: Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100:2243-2245, 2002
11. Lazarus HM, Rowe JM: Reduced-intensity conditioning for acute myeloid leukemia: Is this strategy correct. Leukemia 20:1673-1682, 2006
12. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ: Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23:5675-5687, 2005
13. Sayer HG, Kroger M, Beyer J, et al: Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 31:1089-1095, 2003
14. Hallemeier C, Girgis M, Blum W, et al: Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants. Biol Blood Marrow Transplant 10:310-319, 2004
15. Hegenbart U, Niederwieser D, Sandmaier BM, et al: Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 24:444-453, 2006
16. Claxton DF, Ehmann C, Rybka W: Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation. Br J Haematol 130:256-264, 2005
17. Miller KB, Roberts TF, Chan G, et al: A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant 33:881-889, 2004
18. Platzbecker U, Thiede C, Fussel M, et al: Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 20:707-714, 2006
19. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997
20. Gomez-Nunez M, Martino R, Caballero MD, et al: Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results from the Spanish multicenter prospective trial. Bone Marrow Transplant 33:477-482, 2004
21. Kaplan EL MP: Non parametric estimation from incomplete observations. J Am StatAssoc 53:457-481, 1958
22. Klein JP, Rizzo JD, Zhang MJ, Keiding N: Statistical methods for the analysis and presentation of the results of bone marrow transplants: Part 2-Regression modeling. Bone Marrow Transplant 28:1001-1011, 2001
23. Klein JP, Rizzo JD, Zhang MJ, Keiding N: Statistical methods for the analysis and presentation of the results of bone marrow transplants: Part I - Unadjusted analysis. Bone Marrow Transplant 28:909-915, 2001
24. Baron F, Maris MB, Sandmaier BM, et al: Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23:1993-2003, 2005
25. Appelbaum FR, Pearce SF: Hematopoietic cell transplantation in first complete remission versus early relapse. Best Pract Res Clin Haematol 19:333-339, 2006
26. de Lima M, Giralt S: Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol 43:107-117, 2006
27. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
28. Filipovich AH, Weisdorf D, Pavletic S, et al: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I - Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945-956, 2005
29. Valcarcel D, Martino R, Caballero D, et al: Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 31:387-392, 2003
30. Martino R, Parody R, Fukuda T, et al: Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 108:2928-2936, 2006
31. Shimoni A, Hardan I, Shem-Tov N, et al: Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 20:322-328, 2006
32. Childs R, Clave E, Contentin N, et al: Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 94:3234-3241, 1999
33. Feinstein LC, Sandmaier BM, Hegenbart U, et al: Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 120:281-288, 2003
34. Ho AY, Pagliuca A, Kenyon M, et al: Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104:1616-1623, 2004
35. Andersson BS, Thall PF, Madden T, et al: Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 8:477-485, 2002
36. Clift RA, Buckner CD, Appelbaum FR, et al: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 76:1867-1871, 1990
37. de Lima M, Anagnostopoulos A, Munsell M, et al: Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 104:865-872, 2004
38. Porter D, Levine JE: Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. Semin Hematol 43:53-61, 2006
39. Levine JE, Braun T, Penza SL, et al: Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 20:405-412, 2002
40. Marks DI, Lush R, Cavenagh J, et al: The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 100:3108-3114, 2002